11.74% -0.0359

Nkgen Biotech Inc (NKGN)

Überblick Nachrichten Preisverlauf Warum fällt NKGN? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1170)

Biotechnology (659)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NKGN's Discussions on Twitter

Vergleichen Sie NKGN mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NKGN Nkgen Biotech Inc	0.27	0	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	465.46	123.00B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	548.29	59.66B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	321.28	41.84B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	568.93	33.98B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	288.91	27.67B	3.81B	-644.79M	-669.77M	-6.24

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Es liegen keine Finanzdaten für Nkgen Biotech Inc (NKGN) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

Vergleichen Sie NKGN mit anderen Aktien

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire

NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World

Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Nasdaq

Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance

NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World

NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa

NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com

NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire

Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan

Revolutionary NK Cell Therapy for Alzheimer's Expands Clinical Trial to International Sites - Stock Titan

NKGNW SEC FilingsNKGen Biotech 10-K, 10-Q, 8-K Forms - Stock Titan

Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada

NKGen Biotech Enters Stock Purchase Agreement - TipRanks

NKGen Biotech Delays Quarterly Report Filing - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire

NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks

NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan

NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq

NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan

Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World

NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India

NKGen Biotech secures amended loan terms with East West Bank - Investing.com

NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World

NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire

Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo

Breakthrough: NK Cell Therapy Reverses Moderate Alzheimer's to Mild in Clinical Trial - Stock Titan

NKGen Biotech Delays Annual Report Filing - TipRanks

3 Stocks Near 52-Week Lows With Strong Rebound Potential - The Globe and Mail

NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq

NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire

Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire

NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq

NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire

Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan

NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa

NKGen Biotech secures $5 million convertible loan - Investing.com India

4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks

NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa

NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India

NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire

NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan

NKGen Biotech, Inc. SEC 10-Q Report - TradingView

Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program - Marketscreener.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program - The Manila Times

NKGen Biotech announces administration of first dose of troculeucel - TipRanks

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NKGN